Literature DB >> 27652999

FGF-23 and cardiovascular disease: review of literature.

Jasveen Batra1, Rupinder Singh Buttar, Pardeep Kaur, Jacqueline Kreimerman, Michal L Melamed.   

Abstract

PURPOSE OF REVIEW: This review examines associations between fibroblast growth factor 23 (FGF-23) and cardiovascular disease. RECENT
FINDINGS: FGF-23 is a hormone produced by osteocytes and osteoblasts that aids with phosphate excretion by the kidney and acts as a negative feedback regulator for activated vitamin D synthesis. Recent studies have found associations between elevated FGF-23 levels and a number of cardiovascular diseases, including hypertension, left ventricular hypertrophy, endothelial dysfunction, cardiovascular events and mortality.
CONCLUSION: Recent studies have explored the possible effects of FGF-23 on the cardiovascular system. In animal and observational human studies, there is a link between elevated FGF-23 levels and multiple cardiovascular outcomes, including hypertension, left ventricular hypertrophy and cardiovascular events and mortality. Further studies are required to evaluate whether decreasing FGF-23 levels improves cardiovascular outcomes.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27652999      PMCID: PMC6936216          DOI: 10.1097/MED.0000000000000294

Source DB:  PubMed          Journal:  Curr Opin Endocrinol Diabetes Obes        ISSN: 1752-296X            Impact factor:   3.243


  69 in total

1.  Randomized trial assessing the effects of ergocalciferol administration on circulating FGF23.

Authors:  Sherri-Ann M Burnett-Bowie; Benjamin Z Leder; Maria P Henao; Chantel M Baldwin; Douglas L Hayden; Joel S Finkelstein
Journal:  Clin J Am Soc Nephrol       Date:  2012-02-02       Impact factor: 8.237

2.  Serum fibroblast growth factor-23 and incident hypertension: the Atherosclerosis Risk in Communities (ARIC) Study.

Authors:  Amber L Fyfe-Johnson; Alvaro Alonso; Elizabeth Selvin; Julie K Bower; James S Pankow; Sunil K Agarwal; Pamela L Lutsey
Journal:  J Hypertens       Date:  2016-07       Impact factor: 4.844

3.  Intact fibroblast growth factor 23 levels predict incident cardiovascular event before but not after the start of dialysis.

Authors:  Chikako Nakano; Takayuki Hamano; Naohiko Fujii; Yoshitsugu Obi; Isao Matsui; Kodo Tomida; Satoshi Mikami; Kazunori Inoue; Akihiro Shimomura; Yasuyuki Nagasawa; Noriyuki Okada; Yoshiharu Tsubakihara; Hiromi Rakugi; Yoshitaka Isaka
Journal:  Bone       Date:  2012-03-06       Impact factor: 4.398

Review 4.  Serum phosphorus, cardiovascular and all-cause mortality in the general population: A meta-analysis.

Authors:  Wenwei Bai; Jing Li; Juan Liu
Journal:  Clin Chim Acta       Date:  2016-07-27       Impact factor: 3.786

5.  PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: a bone parathyroid feedback loop.

Authors:  Vardit Lavi-Moshayoff; Gilad Wasserman; Tomer Meir; Justin Silver; Tally Naveh-Many
Journal:  Am J Physiol Renal Physiol       Date:  2010-08-04

6.  Fibroblast growth factor-23 and cardiovascular events in CKD.

Authors:  Julia J Scialla; Huiliang Xie; Mahboob Rahman; Amanda Hyre Anderson; Tamara Isakova; Akinlolu Ojo; Xiaoming Zhang; Lisa Nessel; Takayuki Hamano; Juan E Grunwald; Dominic S Raj; Wei Yang; Jiang He; James P Lash; Alan S Go; John W Kusek; Harold Feldman; Myles Wolf
Journal:  J Am Soc Nephrol       Date:  2013-10-24       Impact factor: 10.121

7.  Serum levels of soluble secreted α-Klotho are decreased in the early stages of chronic kidney disease, making it a probable novel biomarker for early diagnosis.

Authors:  Yoshiko Shimamura; Kazu Hamada; Kosuke Inoue; Koji Ogata; Masayuki Ishihara; Toru Kagawa; Mari Inoue; Shimpei Fujimoto; Mika Ikebe; Kenji Yuasa; Shigeo Yamanaka; Teturo Sugiura; Yoshio Terada
Journal:  Clin Exp Nephrol       Date:  2012-03-29       Impact factor: 2.801

8.  Klotho and phosphate are modulators of pathologic uremic cardiac remodeling.

Authors:  Ming Chang Hu; Mingjun Shi; Han Jun Cho; Beverley Adams-Huet; Jean Paek; Kathy Hill; John Shelton; Ansel P Amaral; Christian Faul; Masatomo Taniguchi; Myles Wolf; Markus Brand; Masaya Takahashi; Makoto Kuro-O; Joseph A Hill; Orson W Moe
Journal:  J Am Soc Nephrol       Date:  2014-10-17       Impact factor: 10.121

9.  Pilot study of dietary phosphorus restriction and phosphorus binders to target fibroblast growth factor 23 in patients with chronic kidney disease.

Authors:  Tamara Isakova; Orlando M Gutiérrez; Kelsey Smith; Michael Epstein; Leigh K Keating; Harald Jüppner; Myles Wolf
Journal:  Nephrol Dial Transplant       Date:  2010-07-14       Impact factor: 5.992

10.  Mineral metabolism, mortality, and morbidity in maintenance hemodialysis.

Authors:  Geoffrey A Block; Preston S Klassen; J Michael Lazarus; Norma Ofsthun; Edmund G Lowrie; Glenn M Chertow
Journal:  J Am Soc Nephrol       Date:  2004-08       Impact factor: 10.121

View more
  13 in total

1.  Associations between endogenous sex hormones and FGF-23 among women and men in the Multi-Ethnic Study of Atherosclerosis.

Authors:  Oluseye Ogunmoroti; Olatokunbo Osibogun; Di Zhao; Rupal C Mehta; Pamela Ouyang; Pamela L Lutsey; Cassianne Robinson-Cohen; Erin D Michos
Journal:  PLoS One       Date:  2022-05-25       Impact factor: 3.752

2.  Assessment of Surrogate Markers for Cardiovascular Disease in Familial Mediterranean Fever-Related Amyloidosis Patients Homozygous for M694V Mutation in MEFV Gene.

Authors:  Sezgin Sahin; Micol Romano; Ferhat Guzel; David Piskin; Dimitri Poddighe; Siren Sezer; Ozgur Kasapcopur; C Thomas Appleton; Ilker Yilmaz; Erkan Demirkaya
Journal:  Life (Basel)       Date:  2022-04-25

3.  Elevated serum fibroblast growth factor 23 levels as an indicator of lower extremity atherosclerotic disease in Chinese patients with type 2 diabetes mellitus.

Authors:  Xingxing He; Xiang Hu; Xiaojing Ma; Hang Su; Lingwen Ying; Jiahui Peng; Xiaoping Pan; Yuqian Bao; Jian Zhou; Weiping Jia
Journal:  Cardiovasc Diabetol       Date:  2017-06-15       Impact factor: 9.951

4.  FGF-23 correlates with endocrine and metabolism dysregulation, worse cardiac and renal function, inflammation level, stenosis degree, and independently predicts in-stent restenosis risk in coronary heart disease patients underwent drug-eluting-stent PCI.

Authors:  Tingting Song; Yang Fu; Yanbo Wang; Wei Li; Jiayu Zhao; Xun Wang; Haiyan Wang; Ying Zhao; Xianghua Fu
Journal:  BMC Cardiovasc Disord       Date:  2021-01-07       Impact factor: 2.298

Review 5.  Association between Endodontic Infection, Its Treatment and Systemic Health: A Narrative Review.

Authors:  Sadia Ambreen Niazi; Abdulaziz Bakhsh
Journal:  Medicina (Kaunas)       Date:  2022-07-14       Impact factor: 2.948

6.  Plasma Fibroblast Growth Factor 23 as a Predictor for Fosinopril Therapeutic Efficacy in Pediatric Primary Hypertension.

Authors:  Yao Lin; Yaxi Cui; Yue Yuan; Lu Gao; Qirui Li; Xiaolan Huang; Yanyan Liu; Lin Shi
Journal:  J Am Heart Assoc       Date:  2022-03-24       Impact factor: 6.106

7.  Effects of recombinant human growth hormone on protein malnutrition and IGF-1 and IL-2 gene expression levels in chronic nephrotic syndrome.

Authors:  Guang Dai; Donghai Wang; Hua Dong
Journal:  Exp Ther Med       Date:  2018-03-13       Impact factor: 2.447

8.  Nonlinear causal effects of estimated glomerular filtration rate on myocardial infarction risks: Mendelian randomization study.

Authors:  Sehoon Park; Soojin Lee; Yaerim Kim; Semin Cho; Hyeok Huh; Kwangsoo Kim; Yong Chul Kim; Seung Seok Han; Hajeong Lee; Jung Pyo Lee; Kwon Wook Joo; Chun Soo Lim; Yon Su Kim; Dong Ki Kim
Journal:  BMC Med       Date:  2022-02-03       Impact factor: 8.775

Review 9.  FGF23 Actions on Target Tissues-With and Without Klotho.

Authors:  Beatrice Richter; Christian Faul
Journal:  Front Endocrinol (Lausanne)       Date:  2018-05-02       Impact factor: 5.555

10.  Genetically Predicted Fibroblast Growth Factor 23 and Major Cardiovascular Diseases, Their Risk Factors, Kidney Function, and Longevity: A Two-Sample Mendelian Randomization Study.

Authors:  Ying Liang; Shan Luo; C Mary Schooling; Shiu Lun Au Yeung
Journal:  Front Genet       Date:  2021-07-23       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.